Investment Thesis
Provectus Biopharmaceuticals is in severe financial distress with negative stockholders' equity of -$6.3M and critically depleted cash reserves of only $251.3K against a -$3.3M annual operating burn rate, indicating imminent liquidity failure. Despite 259.8% revenue growth, the company's 7.3% gross margin and -1615.8% net margin demonstrate a fundamentally broken business model with operating losses of $5.3M that dwarf minimal top-line gains, leaving approximately 30 days of cash runway.
Strengths
- Revenue growth of 259.8% YoY demonstrates market traction in a pharmaceutical niche
- Zero long-term debt eliminates refinancing risk in near-term
- Active insider trading activity (14 Form 4 filings) suggests ongoing management/development
Risks
- Negative stockholders' equity of -$6.3M indicates technical insolvency and balance sheet collapse
- Critical liquidity crisis: $251.3K cash against -$3.3M annual burn rate (30-day runway)
- Unsustainable cost structure: -$1615.8% net margin means company loses $16.16 per dollar of revenue
- Non-controlling expenses: operating losses of -$5.3M vs revenues of $336.1K show zero expense discipline
- No capital expenditure or R&D investment capability signals inability to fund product development
Key Metrics to Watch
- Monthly cash burn rate and remaining runway to insolvency
- Revenue sustainability and gross margin expansion
- Emergency financing activity or debt raises
- Operating expense reduction initiatives and path to cash flow breakeven
Financial Metrics
Revenue
336.1K
Net Income
-5.4M
EPS (Diluted)
$-0.01
Free Cash Flow
-3.3M
Total Assets
697.5K
Cash
251.3K
Profitability Ratios
Gross Margin
7.3%
Operating Margin
-1,575.3%
Net Margin
-1,615.8%
ROE
N/A
ROA
-778.6%
FCF Margin
-989.6%
Balance Sheet & Liquidity
Current Ratio
0.08x
Quick Ratio
0.08x
Debt/Equity
N/A
Debt/Assets
1,003.6%
Interest Coverage
-991.90x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T19:03:22.126216 |
Data as of: 2025-12-31 |
Powered by Claude AI